FDA approves Jardiance tablets to reduce the risk of cardiovascular death in adults with T2D
The only oral T2D medicine to provide a life-saving cardiovascular benefit.
FDA has approved a new indication for Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease. Jardiance is the first type 2 diabetes treatment approved with this additional indication and the only oral T2D medicine shown in a clinical trial to provide a life-saving cardiovascular benefit. Jardiance is marketed by Boehringer Ingelheim and Eli Lilly.
"As the only diabetes treatment approved by the FDA to reduce the risk of cardiovascular death, Jardiance represents a tremendous step forward in our efforts to reduce the impact of heart disease among adults with T2D and cardiovascular disease," said Paul Fonteyne, president and CEO, Boehringer Ingelheim Pharmaceuticals. "This approval is another example of our commitment to the discovery and development of treatment options for adults with T2D. We believe that Jardiance is an important treatment option for this patient population."
"People with diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes. The new indication for empagliflozin enables physicians for the first time to provide adults with type 2 diabetes with a diabetes medication that can reduce their risk of dying from cardiovascular disease," said Christopher P. Cannon, M.D., Cardiovascular Division, Brigham and Women's Hospital and professor of medicine, Harvard Medical School. "It also gives physicians an opportunity to speak with and educate people with T2D about their increased risk for cardiovascular disease and to help them understand this serious complication of their condition."
"Despite significant medical advances, approximately two out of three people with T2D still die from cardiovascular disease. The Boehringer Ingelheim and Lilly diabetes alliance is proud to bring a groundbreaking innovation to millions of adults with T2D and established cardiovascular disease," said Enrique Conterno, senior vice president and president, Lilly Diabetes. "As part of our ongoing commitment to people with T2D, we are also expanding our efforts to educate the public on the link between cardiovascular disease and T2D."
The approval is based on breakthrough evidence from the landmark EMPA-REG OUTCOME trial, which investigated the effects of Jardiance compared with placebo when added to standard of care T2D and cardiovascular medicines in adults with T2D and established cardiovascular disease. In the trial, Jardiance significantly reduced the risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo; absolute risk reduction was 1.6% for Jardiance versus placebo. This primary finding was driven by a significant 38% reduction in the risk of cardiovascular death; absolute risk reduction was 2.2% for patients taking Jardiance versus placebo. There was no change in the risk of non-fatal heart attack or non-fatal stroke. The cardiovascular benefits of Jardiance were consistent among patient subgroups.
Adults with T2D should not take Jardiance if they have severe kidney problems or are on dialysis, or if they are allergic to empagliflozin or any ingredient in Jardiance. Jardiance can cause dehydration and low blood pressure. Jardiance can also cause increased ketones in the blood (ketoacidosis), serious urinary tract infection, acute kidney injury and impairment in renal function, low blood glucose when used with insulin or insulin secretagogues (e.g., sulfonylurea, a medication used to treat T2D), vaginal yeast infections and yeast infections of the penis, and increased cholesterol.
In 2014, Jardiance was approved by the FDA as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance